Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490961 | ||
| 003 | CHVBK | ||
| 005 | 20210128100507.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150601xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0727-x |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0727-x | ||
| 245 | 0 | 0 | |a Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice |h [Elektronische Daten] |c [Joaquín Gavilá, Ángel Guerrero, Miguel Climent, Aranzazu Fernández, Francisco Gozalbo, María Carrascosa, Josefina Camps, Vicente Guillem, Amparo Ruiz] |
| 520 | 3 | |a Background: Based on previous results obtained with non-pegylated liposomal-encapsulated doxorubicin (TLC-D99) together with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer (BC), a similar regimen was evaluated in the neoadjuvant setting in a prospectively selected series of consecutive patients with clinical stage II-III BC. Primary and secondary objectives included the rate of pathologic complete response (pCR), safety, and predictive factors of pCR. Methods: Patients received six cycles of TLC-D99 (50mg/m2 every 3weeks), paclitaxel (80mg/m2 weekly) and trastuzumab (4mg/kg initial dose and 2mg/kg weekly). All patients underwent surgery after treatment. pCR was defined as the absence of invasive cancer cells in the breast and the axilla. Results: Sixty-two patients with a median age of 46.6 years were analyzed. Stage IIIA was diagnosed in 43.5% of patients and 14.5% had inflammatory BC. Conservative surgery was performed in 46.8% of the patients and pCR was achieved in 63% (95% CI 50.5-75.5). Patients with estrogen receptor (ER)-negative tumors presented a significantly higher pCR rate than patients with ER-positive tumors (74.4 vs 43.5%; P=0.028). Forty-five patients (72.6%) completed study treatment and 80.6% received at least five treatment cycles. No patients developed congestive heart failure and 14.5% of patients showed a≥10% decrease in the left ventricular ejection fraction. Conclusion: The triple combination therapy assessed is effective and safe, offering a high pCR rate in patients with HER2-positive BC. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Antibodies |2 nationallicence | |
| 690 | 7 | |a Breast neoplasm |2 nationallicence | |
| 690 | 7 | |a Drug therapy |2 nationallicence | |
| 690 | 7 | |a Prospective study |2 nationallicence | |
| 690 | 7 | |a Treatment outcome |2 nationallicence | |
| 700 | 1 | |a Gavilá |D Joaquín |u Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | |
| 700 | 1 | |a Guerrero |D Ángel |u Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | |
| 700 | 1 | |a Climent |D Miguel |u Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | |
| 700 | 1 | |a Fernández |D Aranzazu |u Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | |
| 700 | 1 | |a Gozalbo |D Francisco |u Pathological Anatomy Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | |
| 700 | 1 | |a Carrascosa |D María |u Radiation Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | |
| 700 | 1 | |a Camps |D Josefina |u Surgery Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | |
| 700 | 1 | |a Guillem |D Vicente |u Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | |
| 700 | 1 | |a Ruiz |D Amparo |u Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 480-489 |x 1341-9625 |q 20:3<480 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0727-x |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0727-x |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Gavilá |D Joaquín |u Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Guerrero |D Ángel |u Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Climent |D Miguel |u Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Fernández |D Aranzazu |u Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Gozalbo |D Francisco |u Pathological Anatomy Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Carrascosa |D María |u Radiation Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Camps |D Josefina |u Surgery Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Guillem |D Vicente |u Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ruiz |D Amparo |u Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 480-489 |x 1341-9625 |q 20:3<480 |1 2015 |2 20 |o 10147 | ||